結核の管理
PMID 2106816.
1 2 Dye C, Watt CJ, Bleed DM, Williams BG; Watt; Bleed; Williams (2003). “What is the limit to case detection under the DOTS strategy for tuberculosis control?”. Tuberculosis 83 (1?3): 35?43. doi:10.1016/S1472-9792(02)00056-2. PMID 12758187.
↑ Grange JM; Zumla A (June 2002). “The global emergency of tuberculosis: what is the cause?”. The Journal of the Royal Society for the Promotion of Health 122 (2): 78?81. doi:10.1177/146642400212200206. PMID 12134771.
↑ Harries AD, Jahn A, Zachariah R, Enarson D; Jahn; Zachariah; Enarson (June 2008). “Adapting the DOTS framework for tuberculosis control to the management of non-communicable diseases in sub-Saharan Africa”. PLoS Medicine 5 (6): e124. doi:10.1371/journal.pmed.0050124.
[http://aac.asm.org/cgi/reprint/48/8/3133.pdf “Lack of Activity of Orally Administered Clof azimine against Intracellular Mycobacterium tuberculosis in Whole-Blood Culture”] (PDF). Antimicrob Agents Chemother 48 (8): 3133–35. doi:10.1128/AAC.48.8.3133-3135.2004. PMC 478499. PMID 15273133. http://aac.asm.org/cgi/reprint/48/8/3133.pdf.
↑ Shubin H; Sherson J; Pennes E; Glaskin A; Sokmensuer A. (1958). “Prochlorperazine (compazine) as an aid in the treatment of pulmonary tuberculosis”. Antibiotic Med Clin Ther. 5 (5): 305–09. PMID 13521769.
↑ “Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis”. Antimicrob Agents Chemother 38 (9): 2054–58. (1994). doi:10.1128/AAC.38.9.2054. PMC 284683. PMID 7811018.
↑ http://www.iblogscience.com/incidence-of-extrapulmonary-tb-trending-upward-2/
↑ Gallardo, CR; Rigau Comas, D; Valderrama Rodriguez, A; Roque I Figuls, M; Parker, LA; Cayla, J; Bonfill Cosp, X (17 May 2016). “Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis.”. The Cochrane Database of Systematic Reviews 5: CD009913. doi:10.1002/14651858.CD009913.pub2. PMC 4916937. PMID 27186634. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009913.pub2/full 2016年6月6日閲覧。.
↑ “Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis”. American Journal of Respiratory and Critical Care Medicine 167 (11): 1472?77. (June 2003).
0b013e3182154b05. PMID 21378593.
↑ Ziganshina, Lilia E; Squire, Stephen B (2008). “Fluoroquinolones for treating tuberculosis”. Cochrane Database of Systematic Reviews (1): CD004795. doi:10.1002/14651858.CD004795.pub3. PMID 18254061.
↑ “Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study”. Lancet 365 (9456): 318?26. (2005). doi:10.1016/S0140-6736(05)17786-1. PMID 15664227. http://linkinghub.elsevier.com/retrieve/pii/S0140673605177861.
↑ “Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis”. Eur Respir J 21 (3): 483–88. (2003). doi:10.1183/09031936.03.00090702. PMID 12662006. http://erj.ersjournals.com/cgi/content/abstract/21/3/483.
↑ Jenny‐Avital1 ER, Joseph K (2009). “Rifamycin‐resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: A report of 3 relapses with acquired rifampin resistance following alternate‐day rifabutin and boosted protease inhibitor therapy”. Clin Infect Dis 48 (10): 1471–74. doi:10.1086/598336. PMID 19368504. https://academic.oup.com/cid/article/48/10/1471/425080.
↑ “Severe cutaneous hypersensitivity reactions during treatment of tuberculosis in patients with HIV infection in Tanzania”. Trop Geogr Med 44 (4): 308–11. (1992). PMID 1284179.
↑ “HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon”.
Clin Pharmacol Ther 32 (4): 525–30. (1982). doi:10.1038/clpt.1982.197. PMID 7116768.
↑ “Calcium metabolism during rifampicin and isoniazid therapy for tuberculosis”. J R Soc Med 75 (7): 533?36. (1982). PMC 1437875. PMID 7086805. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1437875/.
↑ “Long term study of the effect of rifampicin and isoniazid on vitamin D metabolism”. Tubercle 66 (1): 49–54. (1985). doi:10.1016/0041-3879(85)90053-4. PMID 3838603.
↑ Chan TY (1996). “Osteomalacia during rifampicin and isoniazid therapy is rare in Hong Kong”. Int J Clin Pharmacol Ther 34 (12): 533?34. PMID 8996847.
↑ “Tuberculosis and chronic hepatitis B virus infection in africans and variation in the vitamin D receptor gene”. J Infect Dis 179 (3): 721–24.
Int J Tuberc Lung Dis 8 (12): 1484?91. PMC 2912521. PMID 15636496. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912521/.
↑ Sinclair, D; Abba, K; Grobler, L; Sudarsanam, TD (9 November 2011). “Nutritional supplements for people being treated for active tuberculosis.”. The Cochrane Database of Systematic Reviews (11): CD006086. doi:10.1002/14651858.CD006086.pub3. PMC 4981643. PMID 22071828. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981643/.
↑ “Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis”. Int J Epidemiol 37 (1): 113?19. (2008). doi:10.1093/ije/dym247. PMID 18245055.
↑ Davies PD (1985). “A possible link between vitamin D deficiency and impaired host defence to Mycobacterium tuberculosis”. Tubercle 66 (4): 301–06.
2010年、他の国比べてインドで結核に罹った患者が多数報告されている。 インド政府の個人健康部門での結核の診断と処置に対する厳しいミスがあったのが発覚して、人口の50%近くが結核に罹った。それ故に、インドの個人健康部門に政府の公共プログラムが施行され、政府を通じて結核に罹った患者へのプログラムにより、効果的に結核患者が減った。加えて、マウラヤの治験で2013年に結核の治療について証明された指導方法により、インドでの多剤耐性結核の病気としての重荷と、多剤耐性結核検査での症状の変化を監視、調査、管理が行われた。